Figure 4.

Inhibition of BL cell proliferation by ibrutinib in combination with carfilzomib, idelalisib or doxorubicin. Raji cells were treated with ibrutinib (Ibr) with varying doses (0, 0.25, 0.5, 1.0, 5.0, and 10 μM) in combination with carfilzomib (CFZ) (A), idelalisib (B), or doxorubicin (dox) (C) for five days. The doses of CFZ, idelalisib, and dox were indicated in the figures. Ibrutinib was dissolved in DMSO. DMSO (ibrutinib dose at 0 without any other drug) was used as control. The second and the third grey bars in A with ibrutinib dose at 0 represent the cells treated with carfilzomib alone. The second grey bar in B with ibrutinib dose at 0 represents the cells treated with idelalisib alone. The second and the third grey bars in C with ibrutinib dose at 0 represent the cells treated with doxorubicin alone. Cell proliferation was examined by CellTiter 96® Aqueous One solution cell proliferation assays. Cell proliferation fold change was calculated by the equation: treated A490 reading/DMSO A490 reading. DMSO A490 reading was set as 1. IC₅₀ was determined with CompuSyn software.